Skip to main content

People in the News: Sep 30, 2010 (rev. 1)


Predictive Biosciences this week appointed Thomas Ross as chief commercial officer and Randal Vader as vice president of clinical and regulatory affairs.

Ross most recently served as vice president of North American molecular diagnostic sales at Qiagen. Prior to that, he worked for Digene (now part of Qiagen), where he was responsible for driving expansion of physician and laboratory sales, Predictive said.

Vader most recently was senior vice president of quality, regulatory, and clinical affairs at Orthofix. Prior to that, he worked for EraGen Biosciences, where he helped obtain US Food and Drug Administration clearance for Eragen's herpes simplex virus molecular diagnostic test.

UK-based molecular diagnostics company Biofortuna said this week that it recently named David Whitcombe as non-executive director.

Whitcombe was previously a co-founder of DxS, which Qiagen acquired last year.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.